PIPGEN - PhD Project 12: Treg evolution in B cell lymphoma patients under Idelalisib.
Research · Institut national de la santé et de la recherche > France
RESEARCH PROFILE: First Stage Researcher (R1)
APPLICATION DEADLINE: 27 June 2021
EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020
MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 955534
 First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.
PhD Project details
The PI3Kδ inhibitor, Idelalisib (IDL), is approved for chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), but induces many toxicities. In other B-cell indolent lymphomas, clinical responses are also reported, but with fewer tolerance concerns. The reason for this high activity and fewer safety issues observed in a cohort of CLL/FL patients (treated at IUCTO) is not understood. To identify cellular mechanisms at the origin of these differential responses, ESR12 will: analyse single-cell experiments in spleen from FL or splenic marginal zone lymphoma (SMZL) patients, monitor the evolution of patient circulating immune cell population (incl. Treg) under treatment to explain activity/toxicities, investigate activity/toxicity events linked to other PI3Kδ drug and dissect molecular mechanisms linked to heterogeneity of response ex vivo.
Host: Institut national de la santé et de la recherche / Université de Toulouse III (INSERM), France.
Supervisors: Dr. Julie Guillermet-Guibert and Dr. Loïc Ysebaert.
Doctoral programme: Université Toulouse III – Paul Sabatier.
Envisioned secondments: iOnctura, ErasmusMC.